Relay Therapeutics, Inc.
RLAYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Valued at $4.17B, RLAY is a mid-cap name in its sector. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$4.17B
Beta
1.70
P/E (TTM)
—
P/E (Fwd)
-11.63
EPS (TTM)
$-1.56
EPS (Fwd)
$-1.64
ROE
-36.8%
ROA
-22.9%
Cash
$910.9M
Total Debt
$30.7M
Free CF
-$119.2M
52W Change
367.8%
Annual Financials
Cash vs Debt
Where RLAY stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, RLAY finished 41.34% above its 150-day moving average ($13.98) and 59.48% above its 200-day moving average ($12.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RLAY overbought or oversold?
At the August 25, 2026 close, RLAY's RSI(14) was 53.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $910.9M in cash comfortably exceeding the $30.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$119.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -36.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.4M (2022) to $15.4M (2025), reflecting a 1012% increase over the period.
Relay Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, RLAY has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Relay Therapeutics, Inc.'s trajectory.